FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2538837060> ?p ?o ?g. }

• W2538837060 abstract "Few clinical studies have confirmed the role of cytokine-induced killer cells (CIKs) in the maintenance therapy of advanced lung cancer patients. We investigate effectiveness and tolerability of CIKs as a maintenance therapy in the treatment of advanced lung cancer patients.70 patients with advanced lung cancer (stage IIIB to IV) admitted to the First Affiliated Hospital of Third Military Medical University in Chongqing from Nov. 2011 to Jan. 2015 and treated with CIKs were enrolled as a CIKs group (T group), and another 70 advanced lung cancer patients treated with optimal supportive care during the same period were enrolled as a control group(C group). The changes of immune system, response rate, disease control rate, overall survival, and side effects were compared between the two groups. Furthermore, the factors that might influence the efficacy of CIKs therapy were evaluated.Compared with the healthy people, the ratios of CD3+, CD4+ and CD8+ T cells significantly decreased (P<0.05) in lung cancer patients. After CIKs treatment, the ratios of CD3+ and CD4+ T cells and CD4+/CD8+ significantly increased (P<0.05). The response rate (RR) and disease control rate (DCR) were 34.3% and 80.0% in the CIKs group, which were significantly higher than those in the control group (11.4% and 54.3%, both P<0.05). Besides, the median PFS was significantly improved in the CIKs group than that in control group (6 months vs. 4 months, P<0.05). Although median OS was 28 months in CIKs group while 22 months in control group, no significant difference was observed (P>0.05). However, The 2-year, 3-year survival rates were 56.8% and 21.6% in the CIK group, respectively, which were significantly improved compared to that in the control group (both P<0.05). KPS score significantly increased in the CIKs group (P=0.001). 6 patients suffered from transient fever or chills in the process of CIKs transfusion, and no other side effect was observed. Furthermore, we also found that TNM stage, tumor size, metastasis in vital organs and KPS score were all factors associated with efficacy of CIKs treatment.CIKs treatment, as a maintenance therapy, is safe and effective for advanced lung cancer patients, and can also improve the immune imbalance, RR, DCR, PFS, OS and quality of life of the lung cancer patients." @default.
• W2538837060 created "2016-10-28" @default.
• W2538837060 creator A5010422757 @default.
• W2538837060 creator A5024577852 @default.
• W2538837060 creator A5036164745 @default.
• W2538837060 creator A5037797754 @default.
• W2538837060 creator A5066606699 @default.
• W2538837060 creator A5068315400 @default.
• W2538837060 creator A5085205118 @default.
• W2538837060 creator A5088969268 @default.
• W2538837060 date "2016-12-01" @default.
• W2538837060 modified "2023-09-24" @default.
• W2538837060 title "Therapeutic outcomes of autologous CIK cells as a maintenance therapy in the treatment of lung cancer patients: A retrospective study" @default.
• W2538837060 cites W1505828527 @default.
• W2538837060 cites W163992869 @default.
• W2538837060 cites W1796133466 @default.
• W2538837060 cites W1995958455 @default.
• W2538837060 cites W2021288842 @default.
• W2538837060 cites W2032174355 @default.
• W2538837060 cites W2034472677 @default.
• W2538837060 cites W2040602030 @default.
• W2538837060 cites W2052072562 @default.
• W2538837060 cites W2057398467 @default.
• W2538837060 cites W2060192008 @default.
• W2538837060 cites W2064706357 @default.
• W2538837060 cites W2064986515 @default.
• W2538837060 cites W2078907481 @default.
• W2538837060 cites W2080247160 @default.
• W2538837060 cites W2091262320 @default.
• W2538837060 cites W2105954911 @default.
• W2538837060 cites W2106787323 @default.
• W2538837060 cites W2113618705 @default.
• W2538837060 cites W2116778176 @default.
• W2538837060 cites W2124689732 @default.
• W2538837060 cites W2126207954 @default.
• W2538837060 cites W2132224152 @default.
• W2538837060 cites W2139919192 @default.
• W2538837060 cites W2141463948 @default.
• W2538837060 cites W2154866787 @default.
• W2538837060 cites W2170552969 @default.
• W2538837060 cites W2189309587 @default.
• W2538837060 cites W2229874895 @default.
• W2538837060 cites W2398691491 @default.
• W2538837060 cites W2917837889 @default.
• W2538837060 cites W841134900 @default.
• W2538837060 doi "https://doi.org/10.1016/j.biopha.2016.10.022" @default.
• W2538837060 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27764762" @default.
• W2538837060 hasPublicationYear "2016" @default.
• W2538837060 type Work @default.
• W2538837060 sameAs 2538837060 @default.
• W2538837060 citedByCount "6" @default.
• W2538837060 countsByYear W25388370602017 @default.
• W2538837060 countsByYear W25388370602018 @default.
• W2538837060 countsByYear W25388370602019 @default.
• W2538837060 countsByYear W25388370602020 @default.
• W2538837060 countsByYear W25388370602022 @default.
• W2538837060 crossrefType "journal-article" @default.
• W2538837060 hasAuthorship W2538837060A5010422757 @default.
• W2538837060 hasAuthorship W2538837060A5024577852 @default.
• W2538837060 hasAuthorship W2538837060A5036164745 @default.
• W2538837060 hasAuthorship W2538837060A5037797754 @default.
• W2538837060 hasAuthorship W2538837060A5066606699 @default.
• W2538837060 hasAuthorship W2538837060A5068315400 @default.
• W2538837060 hasAuthorship W2538837060A5085205118 @default.
• W2538837060 hasAuthorship W2538837060A5088969268 @default.
• W2538837060 hasConcept C114684123 @default.
• W2538837060 hasConcept C121608353 @default.
• W2538837060 hasConcept C126322002 @default.
• W2538837060 hasConcept C143998085 @default.
• W2538837060 hasConcept C146357865 @default.
• W2538837060 hasConcept C151730666 @default.
• W2538837060 hasConcept C167672396 @default.
• W2538837060 hasConcept C197934379 @default.
• W2538837060 hasConcept C203014093 @default.
• W2538837060 hasConcept C2776256026 @default.
• W2538837060 hasConcept C2777701055 @default.
• W2538837060 hasConcept C2778375690 @default.
• W2538837060 hasConcept C2778594517 @default.
• W2538837060 hasConcept C2779109515 @default.
• W2538837060 hasConcept C71924100 @default.
• W2538837060 hasConcept C86803240 @default.
• W2538837060 hasConcept C8891405 @default.
• W2538837060 hasConcept C90924648 @default.
• W2538837060 hasConceptScore W2538837060C114684123 @default.
• W2538837060 hasConceptScore W2538837060C121608353 @default.
• W2538837060 hasConceptScore W2538837060C126322002 @default.
• W2538837060 hasConceptScore W2538837060C143998085 @default.
• W2538837060 hasConceptScore W2538837060C146357865 @default.
• W2538837060 hasConceptScore W2538837060C151730666 @default.
• W2538837060 hasConceptScore W2538837060C167672396 @default.
• W2538837060 hasConceptScore W2538837060C197934379 @default.
• W2538837060 hasConceptScore W2538837060C203014093 @default.
• W2538837060 hasConceptScore W2538837060C2776256026 @default.
• W2538837060 hasConceptScore W2538837060C2777701055 @default.
• W2538837060 hasConceptScore W2538837060C2778375690 @default.
• W2538837060 hasConceptScore W2538837060C2778594517 @default.
• W2538837060 hasConceptScore W2538837060C2779109515 @default.
• W2538837060 hasConceptScore W2538837060C71924100 @default.
• W2538837060 hasConceptScore W2538837060C86803240 @default.
• W2538837060 hasConceptScore W2538837060C8891405 @default.

• next